Skip to main content
. 2018 Feb 2;32(5):1135–1146. doi: 10.1038/s41375-017-0005-9

Fig. 5.

Fig. 5

AC-4–130 reduces clonogenicity of primary AML patient cancer stem cells. a Characteristics of human AML patients. b Viability assay of human AML patient samples and healthy CD34+ cells treated with AC-4–130 or DMSO (Ctrl) for 48 h. c AML samples and CD34+ cells were embedded in methylcellulose in the presence of AC-4–130 or DMSO (Ctrl). Colonies were counted 10 days after seeding